2024 American Society of
Clinical Oncology Annual Meeting
Friday, May 31 – June 4, 2024
McCormick Place | Chicago, IL
BOOTH #28001
Connect with Caris Life Sciences at ASCO
Join Caris Life Sciences® at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Visit with our team at booth #28001 to discover the latest innovations in precision medicine, and how our products and services are leading the molecular revolution.
Whether you are treating patients in the clinic or building the next wave of therapeutics, be sure to stop by and learn how Caris can support your precision medicine program.
- Comprehensive molecular profiling – no matter the specimen type, tissue or blood:
- Tissue: DNA, RNA and Protein biomarker analysis
- Blood: Caris Assure™ featuring somatic tumor, clonal hematopoiesis and incidental germline* characterization
- Whole exome and whole transcriptome sequencing for every patient
- 23,000 genes via Whole Exome Sequencing (WES – DNA)
- 61,000 transcripts via Whole Transcriptome Sequencing (WTS – RNA)
- AI-Powered Predictive Signatures for metastatic CRC and tumor type confirmation
- Accelerate therapeutic development with Caris Discovery™
- Identify, develop and commercialize your next therapeutic targets
- Make confident decisions with real-world, multi-modal data
Presentations and Posters
Caris and its collaborators from the biopharma industry and leading cancer centers, including those within the Precision Oncology Alliance™ (POA), will collectively present 41 studies, including two rapid oral abstracts and 39 posters, one of which received a merit award. These studies, covering 19 tumor types, demonstrate the power of Caris’ comprehensive clinicogenomic database to enable novel insights into cancer that could profoundly affect a patient’s diagnosis, prognosis, care plan, and response to treatment.
RAPID ORAL PRESENTATIONS:
- Genomic and tumor microenvironment dynamics of brain metastases in breast cancer.
(Abstract Number: 1018)
Monday, June 3; 12:06 PM – 12:12 PM CDT - Clinical utility of transcriptomic signatures to identify androgen receptor and neuroendocrine signaling in prostate cancer.
(Abstract Number: 5015)
Monday, June 3; 2:03 PM – 2:09 PM CDT
MERIT AWARD POSTER:
- The molecular landscape of pembrolizumab and lenvatinib treatment in endometrial cancer.
(Abstract Number: 5612)
Monday, June 3; 9:00 AM – 12:00 PM CDT
Caris Abstracts and Presentation Schedule
Caris’ strong presence at ASCO 2024 demonstrates the clinical value of comprehensive molecular profiling and our commitment to transforming lives through research. Download the abstracts and presentation schedule, including a full list of summaries highlighting the research presented at ASCO 2024.
Certain products and features may vary based on region or territory.
*Not a replacement for comprehensive germline testing. Incidental pathogenic alterations detected in ACMG recognized cancer genes are reported. Negative results do not imply the patient does not harbor a germline mutation.